CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

MANAGEMENT OF HASĀH WA RAML AL-KULYA (NEPHROLITHIASIS) IN UNANI SYSTEM OF MEDICINE: A REVIEW

  • Khan, Khalid Ali (Department of Ilmul Jarahat (Unani surgery), Rajputana Unani Medical College Hospital & Research Centre) ;
  • Khan, Rashid Ali (Department of Amraz-e-Jild wa Zohrawiya wa Tazeeniyat (Unani Dermatology, Cosmetology & Venerology), University College of Unani) ;
  • Zakir, Mohammad (Department of Ilmul Advia (Pharmacology), National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD))
  • Received : 2020.04.16
  • Accepted : 2020.06.02
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

The kidneys are exposed to toxicants and waste product and can be affected easily by these toxicants and by products of the metabolism. The consumption of adequate water is necessary to remove waste and to keep kidney healthy. Deficiency of liquid in the blood leads to various adverse effects on the kidney. The most common adverse deficiency of liquid in blood is deposition of solid matter in the kidney and subsequently formation of kidney stone. Nephrolithiasis (kidney stone) can be treated by drugs if it is small in size but if it blocks the route due to its big size then surgery is the only way to remove it. The recurrence rate of the problem is very high and it may reappear within 10 years. In Unani literature Hasāh wa Raml al-Kulya (nephrolithiasis) is described in detail. As per Unani literature stagnation of Ghalīz mādda (filthy and viscous matter) in the kidney is the main cause of the formation of kidney stone. Various single and compound formulations drugs are described for the management of kidney stone which are very effective as well as safe. Management is divided into two parts i.e. symptomatic treatment to relieve pain and to methods adopted to remove stone from the kidney. Musakkin-i-Waja'(analgesic) drugs are used for pain while Mufattit-i-Hasāh (lithotriptic) and Mudirr-i-Bawl (Diuretic) drugs are used to remove stone. Majoon Aqrab, Qurs Kaknaj and Dawa-e-Gurda etc. are compound drugs mentioned in literature for removal of kidney stone. Single drugs like Alu Balu, Tukhm Khayar, and Kharkhask etc. are also used for same purpose.

Keywords

References

  1. Anonymous. American kidney funds: fighting on all fronts, Maryland (USA). Available at: https://www.kidneyfund.org/kidney-disease/kidney-problems/kidney-stones/ (accessed on 22 April 2020b)
  2. Anonymous. National Formulary of Unani Medicine, Part-I. (2006a). (New Delhi, India: CCRUM, Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2006
  3. Anonymous. National Formulary of Unani Medicine, Part-II, Vol-I. (2007). (New Delhi, India: Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2007.
  4. Anonymous. National Formulary of Unani Medicine, Part-IV, first edition. (2006b). (New Delhi, India: Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2006.
  5. Anonymous. National Formulary of Unani Medicine, Part-VI. (2011). (New Delhi, India: Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2011.
  6. Anonymous. National Kidney Foundation, New York. Available at: https://www.kidney.org/atoz/content/kidneystones (accessed on 22 April 2020a).
  7. Anonymous. Standard Unani Medical Terminology. (New Delhi, India: Central Council for Research in Unani Medicine, Ministry of AYUSH, Govt. of India), 2012
  8. Arzani MA. Meezan al-Tib, National Council for promotion of Urdu language, New Delhi, 1992.
  9. Arzani MA. Tibb-e-Akbar Urdu, Faisal Publisher, Jama Masjid, Deoband, 1924.
  10. Cheungpasitporn W, Thongprayoon C, O'Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, et al. The risk of kidney cancer in patients with kidney stones: A systematic review and meta-analysis. QJM, 2015;108:205-12. https://doi.org/10.1093/qjmed/hcu195
  11. Ghani N. Khazainul Advia.: Idara Kitabul Shifa, New Delhi, India, 2011.
  12. Ibn Sina. al-Shaykh al-Ra'is Abu 'Ali al-Husayn ibn 'Abd Allah (1411AH): Al-Qanun fi'l Tibb, Idara Kitabul Shifa, New Delhi.
  13. Kabir al-Din, Hakim Muhammad. (1894-1976 AD) Ilmul Adviya Nafisi, (New Delhi, India; Aijaz Publishing House), 2007.
  14. Kabir al-Din, Hakim Muhammad. (1894-1976 AD), Kitabul Advia, Vol-II, Makhzanul Mufradat, Daftraul Masih, Hyderbad, 1955.
  15. Khan Ajmal, Hakim Muhammad (1868-1927 AD) Haziq, 27th edition, Hindustani Dawakhana Delhi, 1987, pp. 275-278.
  16. Lieske JC, Pena de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, et al. Renal stone epidemiology in Rochester, Minnesota: An update. Kidney Int, 2006;69:760-4. https://doi.org/10.1038/sj.ki.5000150
  17. Long LO, Park S. Update on nephrolithiasis management. Minerva Urol Nefrol, 2007;59:317-25.
  18. Lopez M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol, 2010; 25:49-59. https://doi.org/10.1007/s00467-008-0960-5
  19. Nafis ibn 'Iwad ibn Jamal al-Din al-Mutatabbib al-Kirmani, (1439 AD), Sharh al-Asbab wa'l 'Alamat, Vol. III-IV, (urdu translation by Hakim Kabiruddin), (New Delhi, India; Aijaz Publishing House), pp. 305-309.
  20. Rule AD, Lieske JC, Li X, Melton LJ rd, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol, 2014;25:2878-86. https://doi.org/10.1681/ASN.2013091011
  21. Shah J, Whitfield HN. Urolithiasis through the ages. BJU Int., 2002;89:801-89:8 https://doi.org/10.1046/j.1464-410X.2002.02769.x
  22. Sofia NH, Manickavasakam K, Walter TM. Prevalence and Risk Factors of Kidney Stone. Global Journal for Research Analysis, 2016;5(3):183-187